FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2037-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-finding study of FT-516 in combination with monoclonal antibodies in
subjects with advanced solid tumors. The study will consist of a dose-escalation stage and an
expansion stage where participants will be enrolled into indication-specific cohorts.